Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 79

Results For "SEC"

2374 News Found

Biocon Biologics recognized as an Asia IP Elite for 2023
News | December 17, 2023

Biocon Biologics recognized as an Asia IP Elite for 2023

Biocon Biologics is one among the three pharmaceutical companies from India to be featured on this year's list


Lupin receives USFDA approval for Allopurinol Tablets
Drug Approval | December 17, 2023

Lupin receives USFDA approval for Allopurinol Tablets

The product will be manufactured at Lupin's Pithampur facility in India


TÜV SÜD inaugurates € 15 million Laboratory & Training Centre Bengaluru Campus
News | December 17, 2023

TÜV SÜD inaugurates € 15 million Laboratory & Training Centre Bengaluru Campus

Expansion of presence in India with electrical safety, electromagnetic compatibility and medical device biocompatibility, toxicity and microbiology testing and certification services


Venus Remedies expands global presence with marketing authorisation for enoxaparin from Azerbaijan
News | December 14, 2023

Venus Remedies expands global presence with marketing authorisation for enoxaparin from Azerbaijan

The company makes its maiden entry into Azerbaijan’s pharmaceutical market


Granules India received ANDA approval for Pantoprazole Sodium Delayed-Release Tablets
Drug Approval | December 14, 2023

Granules India received ANDA approval for Pantoprazole Sodium Delayed-Release Tablets

Pantoprazole Sodium Delayed-Release Tablets are indicated for short-term treatment of Erosive Esophagitis associated with GERD


Merck and Moderna initiate Phase 3 study evaluating V940 (mRNA-4157) in combination with Keytruda for treatment of non-small cell lung cancer
News | December 12, 2023

Merck and Moderna initiate Phase 3 study evaluating V940 (mRNA-4157) in combination with Keytruda for treatment of non-small cell lung cancer

The initiation of the second clinical trial in the INTerpath program represents rapid expansion in research for additional tumor types for individualized neoantigen therapy, V940 (mRNA-4157)


Vertex and CRISPR Therapeutics announce USFDA approval of Casgevy for treatment of sickle cell disease
Drug Approval | December 09, 2023

Vertex and CRISPR Therapeutics announce USFDA approval of Casgevy for treatment of sickle cell disease

Approximately 16,000 patients 12 years of age and older with severe sickle cell disease may now be eligible for this one-time treatment


Sarclisa Phase 3 trial met primary endpoint of progression free survival with newly diagnosed multiple myeloma not eligible for transplant
News | December 08, 2023

Sarclisa Phase 3 trial met primary endpoint of progression free survival with newly diagnosed multiple myeloma not eligible for transplant

Sarclisa added to bortezomib, lenalidomide and dexamethasone (VRd) significantly reduced the risk of disease progression or death compared with VRd alone


Akums acquires new facility in Baddi to enhance tablet manufacturing capacity
News | December 07, 2023

Akums acquires new facility in Baddi to enhance tablet manufacturing capacity

his marks the 12th formulation facility under Akums, and the second in Baddi, a strategic move with an aim to enhance Akums’ manufacturing capabilities.


Venus Remedies gets marketing approvals from Philippines, Saudi Arabia for three drugs
News | December 07, 2023

Venus Remedies gets marketing approvals from Philippines, Saudi Arabia for three drugs

Venus Remedies is supplying the drug to many countries like Colombia, Thailand, Tanzania, Morocco, Myanmar, Indonesia, Saudi Arabia, Malaysia, Zimbabwe, Sri Lanka, Pakistan, Kenya, and Botswana